ETP-ALL are recognized by a distinct immature phenotype, characterized by the expression of at least one stem cell (CD34, CD117) and/or myeloid markers (CD13, CD33, HLA-DR, CD11b, CD65) in at least 25% of leukemic cells, negativity or weak expression (<75%) of CD5, and no expression of CD4 and CD8 [24]. The gene discussed is CD33; the disease is acute lymphoblastic leukemia.